| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Molecular Medicine (N.S., E.R.-B., X.W., L.C., A.F.-M., G.N., P.T.-E.), and Atherosclerosis Research Unit, King Gustaf V Research Institute (R.M.F.), Karolinska Hospital, Karolinska Institute, SE-171 76 Stockholm, Sweden; and Department of Laboratory Medicine, Division of Clinical Pharmacology, Huddinge University Hospital, Karolinska Institute (G.T.), SE-141 86 Stockholm, Sweden
Address all correspondence and requests for reprints to: Dr. Nina Ståhlberg, Karolinska Institute, Department of Molecular Medicine, CMM L8:01, Karolinska Hospital, 171 76 Stockholm, Sweden. E-mail: nina.stahlberg{at}cmm.ki.se.
The aim of this study was to identify genes for hepatic fuel metabolism with a gender-differentiated expression and to determine which of these that might be regulated by the female-specific secretion of GH. Effects of gender and continuous infusion of GH to male rats were studied in the liver using cDNA microarrays representing 3200 genes. Sixty-nine transcripts displayed higher expression levels in females, and 177 displayed higher expression in males. The portion of GH-regulated genes was the same (30%) within the two groups of gender-specific genes. The male liver had a higher expression of genes involved in fuel metabolism, indicating that male rats might have a greater capacity for high metabolic turnover, compared with females. Most notable among the female-predominant transcripts was fatty acid translocase/CD36, with 18-fold higher mRNA levels in the female liver and 4-fold higher mRNA levels in males treated with GH, compared with untreated males. This gender-differentiated expression was confirmed at mRNA and protein levels in the rat and at the mRNA level in human livers. Although purely speculative, it is possible that higher levels of fatty acid translocase/CD36 in human female liver might contribute to the sexually dimorphic development of diseases resulting from or characterized by disturbances in lipid metabolism, such as arteriosclerosis, hyperlipidemia, and insulin resistance.
This article has been cited by other articles:
![]() |
R. W. van der Meer, S. Hammer, H. J. Lamb, M. Frolich, M. Diamant, L. J. Rijzewijk, A. de Roos, J. A. Romijn, and J. W. A. Smit Effects of Short-Term High-Fat, High-Energy Diet on Hepatic and Myocardial Triglyceride Content in Healthy Men J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2702 - 2708. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. van der Meer, L. J. Rijzewijk, M. Diamant, S. Hammer, M. Schar, J. J. Bax, J. W.A. Smit, J. A. Romijn, A. de Roos, and H. J. Lamb The ageing male heart: myocardial triglyceride content as independent predictor of diastolic function Eur. Heart J., June 2, 2008; 29(12): 1516 - 1522. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. B. Rogers, E. J. Theve, Y. Feng, R. C. Fry, K. Taghizadeh, K. M. Clapp, C. Boussahmain, K. S. Cormier, and J. G. Fox Hepatocellular Carcinoma Associated with Liver-Gender Disruption in Male Mice Cancer Res., December 15, 2007; 67(24): 11536 - 11546. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Magkos, B. W. Patterson, B. S. Mohammed, S. Klein, and B. Mittendorfer Women Produce Fewer but Triglyceride-Richer Very Low-Density Lipoproteins than Men J. Clin. Endocrinol. Metab., April 1, 2007; 92(4): 1311 - 1318. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. S. Eyre, L. G. Cleland, N. N. Tandon, and G. Mayrhofer Importance of the carboxyl terminus of FAT/CD36 for plasma membrane localization and function in long-chain fatty acid uptake J. Lipid Res., March 1, 2007; 48(3): 528 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Brodeur, V. Luangrath, G. Bourret, L. Falstrault, and L. Brissette Physiological importance of SR-BI in the in vivo metabolism of human HDL and LDL in male and female mice J. Lipid Res., April 1, 2005; 46(4): 687 - 696. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Rico-Bautista, C. J. Greenhalgh, P. Tollet-Egnell, D. J. Hilton, W. S. Alexander, G. Norstedt, and A. Flores-Morales Suppressor of Cytokine Signaling-2 Deficiency Induces Molecular and Metabolic Changes that Partially Overlap with Growth Hormone-Dependent Effects Mol. Endocrinol., March 1, 2005; 19(3): 781 - 793. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |